Modality
Fusion Protein
MOA
PARPi
Target
VEGF
Pathway
Notch
MigraineGA
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
~Jan 2018
→ ~Apr 2019
Phase 2
~Jul 2019
→ ~Oct 2020
Phase 3
~Jan 2021
→ ~Apr 2022
NDA/BLA
Jul 2022
→ Jun 2031
NDA/BLACurrent
NCT07675662
746 pts·Migraine
2023-08→2031-06·Not yet recruiting
NCT07722426
2,628 pts·Migraine
2022-07→2027-01·Recruiting
3,374 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-01-029mo awayPh3 Readout· Migraine
2031-06-165.2y awayPh3 Readout· Migraine
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
NDA/BLA
Recruit…
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2027-01-02 · 9mo away
Migraine
Ph3 Readout
2031-06-16 · 5.2y away
Migraine
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07675662 | NDA/BLA | Migraine | Not yet recr... | 746 | HAM-D |
| NCT07722426 | NDA/BLA | Migraine | Recruiting | 2628 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 |